Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergic Rhinoconjunctivitis Clear all
Completed Phase 3 Interventional Results available

House Dust Mite Allergy Trial In Children

NCT04145219
View directory record Official record
Conditions
Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
Interventions
Sublingual allergy immunotherapy tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
5 Years to 11 Years
Enrollment
1,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
29
States / cities
Huntington Beach, California • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Jun 26, 2026, 2:57 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of rEV131 in Allergic Rhinitis

NCT00247520
View directory record Official record
Conditions
Hay Fever
Interventions
topical nasal rEV131
Drug
Lead sponsor
Evolutec Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2005 · Synced Jun 26, 2026, 2:57 AM EDT
Not listed Phase 4 Interventional

Ocular Allergy Treatment Practical Impact Trial

NCT01808768
View directory record Official record
Conditions
Allergic Conjunctivitis, Rhinoconjunctivitis
Interventions
Alcaftadine
Drug
Lead sponsor
Starx Research Center, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Edison, New Jersey • Springfield, New Jersey
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

NCT05540717
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Interventions
PQ Grass, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
33
States / cities
Centennial, Colorado • Denver, Colorado • Lexington, Kentucky + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jun 26, 2026, 2:57 AM EDT
Completed No phase listed Observational

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

NCT00985075
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2009 · Synced Jun 26, 2026, 2:57 AM EDT
Completed No phase listed Observational

Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)

NCT00985296
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 2 Interventional

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

NCT02582073
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU, Grass MATA (0.5ml) 5100SU
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

NCT01707069
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Biological
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Exploratory Study of PQ Grass 27600 SU

NCT04687059
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
PQ Grass, Active Placebo, Standard Placebo
Biological · Drug
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Lexington, Kentucky • White Marsh, Maryland • Ocean Township, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

NCT02557633
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Neptune City, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 26, 2026, 2:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Normal Values of Facial Thermography

NCT00411606
View directory record Official record
Conditions
Healthy, Allergy, Allergic Rhinoconjunctivitis
Interventions
Thermography
Procedure
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
7 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2009 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

NCT00955825
View directory record Official record
Conditions
Allergic Rhinitis Due to Grass Pollens
Interventions
300 IR, Placebo
Drug
Lead sponsor
Stallergenes Greer
Industry
Eligibility
18 Years to 65 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects

NCT01966224
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Biological
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

NCT03887026
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

NCT00574379
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
Interventions
Bilastine, Placebo
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Phase III Cat-PAD Study

NCT01620762
View directory record Official record
Conditions
Rhinoconjunctivitis
Interventions
Cat-PAD, Placebo
Drug
Lead sponsor
Circassia Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
52
States / cities
Rolling Hills Estates, California • Colorado Springs, Colorado • Denver, Colorado + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

NCT03931993
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo comparator, Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Edison, New Jersey • Ocean City, New Jersey • Springfield, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 4 Interventional

A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

NCT00655109
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Olopatadine, Fluticasone, Saline, Artificial tears
Drug
Lead sponsor
Greiner, Jack V., OD DO PhD
Individual
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2008 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

NCT00599872
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Standardized Ragweed Allergenic Extract, Placebo
Biological
Lead sponsor
Greer Laboratories
Industry
Eligibility
18 Years to 50 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
30
States / cities
Normal, Illinois • Evansville, Indiana • Iowa City, Iowa + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Jun 26, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy

NCT01353079
View directory record Official record
Conditions
Allergy
Interventions
Short Ragweed Pollen Allergenic Extract, Placebo
Biological
Lead sponsor
Greer Laboratories
Industry
Eligibility
18 Years to 55 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Warrenton, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Jun 26, 2026, 2:57 AM EDT